Stay updated with breaking news from Peter Borchmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Jun 1, 2024--
An Adcetris-based treatment regimen improved progression-free survival and was more tolerable for patients with classical Hodgkin lymphoma.
Four-year progression-free survival outcomes revealed the BrECADD regimen was superior to the eBEACOPP regimen, and BrECADD had a promising benefit-risk profile.
Better efficacy with brentuximab vedotin versus standard chemo, substantially less toxicity
The BrECADD combination had noninferior efficacy and superior tolerability compared with escalated BEACOPP in patients with advanced classical Hodgkin lymphoma, according to data from the phase 3 HD21 trial.